Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNA2 | P51530 | 1/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.56 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.52 |
| ▸ | CLK1 | P49759 | 2/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30275708 | 1.00 | DNA2 (0.56) | DNA2CASP6CTDSP1TDP1CLK1 | |
| SCHEMBL6538378 | 0.89 | DNA2 (0.63) | DNA2CASP6CTDSP1TDP1CLK1 | |
| SCHEMBL28312938 | 0.79 | MAPT (0.57) | DNA2CASP6CTDSP1TDP1CLK1 | |
| SCHEMBL6090060 | 0.79 | DNA2 (0.56) | DNA2CASP6CTDSP1TDP1CLK1 | |
| SCHEMBL29236598 | 0.79 | DNA2 (0.56) | DNA2CASP6CTDSP1TDP1CLK1 | |
| SCHEMBL6587236 | 0.78 | PARP1 (0.51) | DNA2CASP6CTDSP1TDP1CLK1 | |
| SCHEMBL3056048 | 0.77 | TRIM24 (0.57) | DNA2CASP6CTDSP1TDP1CLK1 | |
| SCHEMBL1277854 | 0.77 | DNA2 (0.83) | DNA2CASP6CTDSP1TDP1CLK1 | |
| SCHEMBL6537493 | 0.76 | ALDH1A1 (0.58) | DNA2CASP6CTDSP1TDP1CLK1 | |
| SCHEMBL6538267 | 0.76 | DNA2 (0.63) | DNA2CASP6CTDSP1TDP1CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116874-A1 | HETEROAROMATIC INDOLESULFONAMIDES | SEED THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4704836-A1 | HETEROAROMATIC INDOLESULFONAMIDES | Seed Therapeutics, Inc (US) | 2026-03-11 | — | — | EP | disclosed |
| CN-118184567-B | Process for preparing 3-haloindole derivatives | 常州工程职业技术学院 | 2025-02-18 | — | — | CN | disclosed |
| CN-115666575-B | Compounds and uses thereof | 福宏治疗公司 | 2024-12-10 | — | — | CN | disclosed |
| WO-2024229040-A1 | HETEROAROMATIC INDOLESULFONAMIDES | SEED THERAPEUTICS, INC (US) | 2024-11-07 | — | — | WO | disclosed |
| CN-118184567-A | Process for preparing 3-haloindole derivatives | 常州工程职业技术学院 | 2024-06-14 | — | — | CN | disclosed |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| EP-4132529-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-115666575-A | Compound and use thereof | 福宏治疗公司 | 2023-01-31 | — | — | CN | disclosed |
| EP-1294716-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | Bristol-Myers Squibb Company (US) | 2003-03-26 | — | — | EP | disclosed |
| CN-1396833-A | Integrin expression inhibitors | EISAI CO LTD (JP) | 2003-02-12 | — | — | CN | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-28 | — | — | US | disclosed |
| CN-1079097-C | Heterobicyclic sulfonamide derivatives and sulfonate derivatives | EISAI CO LTD (JP) | 2002-02-13 | — | — | CN | disclosed |
| WO-2001096331-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| US-5767283-A | CHEMICAL INTERMEDIATE FOR 7-N-ORGANOSULFONYL-1H-INDOLE DERIVATIVE ANTITUMOR AGENTS; NONTOXIC | EISAI CO., LTD. (JP) | 1998-06-16 | — | — | US | disclosed |
| US-5721246-A | ANTITUMOR AGENTS; LOW TOXICITY | EISAI CO., LTD. (JP) | 1998-02-24 | — | — | US | disclosed |
| CN-1114506-A | Heterobicyclic sulfonamide derivatives and sulfonate derivatives | EISAI CO LTD (JP) | 1996-01-03 | — | — | CN | disclosed |
| EP-0673937-A1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | DNA2 535/4885CASP6 1841/4885CTDSP1 1308/4885 |
| US-20260116874-A1 | HETEROAROMATIC INDOLESULFONAMIDES | DCAF1, DCAF15, DDX39B | DNA2 992/4885CASP6 2138/4885CTDSP1 1562/4885 |
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | F9, F7, F11 | DNA2 3950/4885CASP6 382/4885CTDSP1 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.